117 results
8-K
EX-10.6
NKGN
NKGen Biotech Inc
10 May 24
Entry into a Material Definitive Agreement
4:01pm
by a majority of the Borrower’s disinterested directors; provided that, notwithstanding the foregoing Borrower may issue securities pursuant to the conversion … (selected by holders of the majority of the Registrable Securities requesting such registration). In addition, the Company shall be responsible for all of its
8-K
EX-10.3
NKGN
NKGen Biotech Inc
10 May 24
Entry into a Material Definitive Agreement
4:01pm
except for distributions pursuant to any shareholders’ rights plan which is approved by a majority of the Borrower’s disinterested directors; provided
8-K
EX-10.4
i28wj 3ht
10 May 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.2
cw6hm
10 May 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
tsl8t8 zepk1hvwiv9x
10 May 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.5
e7678 pgehg
10 May 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.1
bxz99 san2900
29 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
4ofhfzebqg8c42 zu
11 Apr 24
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
8:05am
8-K
EX-10.3
lma7gg8zw6kkgotop9
11 Apr 24
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
8:05am
8-K
EX-10.4
nmyo1ueukfkw1yimk
5 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
vtv wresn
5 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.2
85w qvto35zwqua7o
5 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.3
umcp6ny 345o
5 Apr 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
6dm7ysdb8
27 Mar 24
Entry into a Material Definitive Agreement
4:55pm